An emerging biotech with transformative potential
About usAnocca is a privately held Swedish biotechnology company founded in 2014 with the mission to establish a unique technology platform for analysis of T-cell biology to unlock the therapeutic potential of T-cell immunity.
Anocca’s technologies enable the highly precise and efficient analysis of T-cell biology required to deliver a range of therapeutics that specifically harness or manipulate T-cell immunity in a number of disease areas. With a focus on delivering TCR-modified T-cell therapies (TCR-T) in oncology, Anocca is rapidly progressing a pipeline of novel T-cell therapies towards clinical trials utilizing our own manufacturing capabilities.
Anocca’s powerful technologies are also being deployed to develop a range of novel therapeutic and prophylactic products in oncology, infectious disease and autoimmunity.

Company leadership
Anocca’s leadership represents diverse backgrounds and experience. Together, the Management team and Board of Directors, with collective experience from the pharmaceutical, engineering and finance sectors, along with deep scientific knowledge and business acumen, are taking the company to the next stage in its development.

Reagan Jarvis

Rolf Kiessling

Hans Stråberg

Mikael Blomqvist

Mike Nishimura

Klas Kärre

Fredrik Hansson

Jacob Michlewicz

Adnane Achour

Luke Pase

Hugh Salter

Ragnar Lindqvist

Ryan Hill

Jan Lundberg

Viktor Arnkil

Reagan Jarvis

Michael Kalos

Mark Farmery

Brian McGee
